Navigation Links
Cephalon Quarterly Conference Call Invitation
Date:6/30/2009

Second Quarter 2009 Earnings Conference Call Tuesday, August 4, 2009, 5:00 p.m. U.S. EDT

FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering second quarter 2009 results for 5:00 p.m. EDT on Tuesday, August 4, 2009.

August 4, 2009 Schedule

    4:10 p.m. EDT   Q2 2009 results will be distributed by PRNewswire
    4:50 p.m. EDT   To participate in the conference call, dial 913-312-0379
                    and refer to Conference Code Number 1696714

    5:00 p.m. EDT   Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at www.cephalon.com and clicking on the "Investors" tab then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EDT, August 11, 2009. To listen to the audio replay, dial 719-457-0820 and use the Conference Code Number 1696714.

Additional information presented on the conference call may be made available on the Investor page of the company's website.

    Contact: Robert S. (Chip) Merritt
    610-738-6376
    cmerritt@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
2. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
3. Cephalons New Product Launches Pace Record 2008 Sales
4. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
5. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
6. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon Reports Another Strong Quarter
9. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
10. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
11. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE will build ... popularity of US Single Day Events (SDE) to organize a multiple-day US conference. ... Raleigh, NC. Topics of the pharmaceutical and life sciences industry will cover industry ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only ... a beautiful technology experience. All three tenets were on display at the 2nd Annual ... from over 40 sponsor, CRO and site organizations to discuss innovation and the future ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, ... in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
Breaking Biology Technology:
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):